Evotec Raised EUR 28.4 Million in Capital Increase
Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announces today that its capital increase of up to 10,457,402 new Evotec shares against contribution in cash has been fully subscripted. The capital increase was authorised by Evotec's shareholders at the Company's AGM on 7 June 2005.
Due to the capital increase, the number of Evotec shares rose from 52,287,013 to 62,744,415. The shares were issued at the fixed price of EUR 2.72 per share, securing Evotec proceeds amounting to EUR 28.4 million. The Company intends to use these funds to advance and expand its proprietary pipeline of drug candidates.
Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.de
Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.de